Company Overview - N Beixin-U is a national high-tech enterprise focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to revolutionize solutions in this field [2][6] - The company's core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration (NMPA) in China, and the fractional flow reserve (FFR) measurement system, which is the first domestically approved product in the gold standard FFR field [2][6] Market Position - N Beixin-U is the first domestic medical device company to have a combination of intravascular functional FFR and imaging IVUS products, filling a gap in the domestic market and changing the reliance on imported products for precise diagnosis of coronary artery diseases in China [2][6] - The company has established a high-performance and high-barrier system for active interventional medical devices, continuously achieving successful research and commercialization of innovative products, gaining recognition in both domestic and international markets [2][6] IPO Details - The company went public today with an opening price of 50.31 yuan, reflecting a 187.16% increase from the issuance price of 17.52 yuan per share [3][7] - A total of 57 million shares were issued, with 13.68 million shares available for online subscription, and the final subscription rate was 0.03264275% [3][7] - The IPO raised approximately 999 million yuan, with funds allocated for the construction of an interventional medical device industrialization base, R&D projects, working capital, and marketing network development [3][7]
N北芯-U今日上市 开盘上涨187.16%